NANETS Symposium | Conference

Dr. Metz Discusses Using a Multidisciplinary Approach When Treating NETs

October 13th 2014

David C. Metz, MBBCh, professor of medicine, co-director, GI Physiology laboratory, Hospital of the University of Pennsylvania, discusses using a multidisciplinary approach to treating neuroendocrine tumors (NETs).

Somatic Mutations in the ATRX Gene Reported for the First Time in Pheochromocytomas/ Paragangliomas

October 13th 2014

Somatic mutations in the ATRX gene are observed in about 13% of pheochromocytomas/paragangliomas, the first such report of somatic ATRX mutations in these tumors.

Dr. Kulke on Unanswered Questions Surrounding the Treatment of NETs

October 13th 2014

Matthew Kulke, MD, comments on some unanswered questions surrounding the treatment of neuroendocrine tumors (NETs).

CDKN1B Mutation May Be Linked to Worse Survival in GEP NETs

October 13th 2014

Low nuclear expression of CDKN1B, a cyclin-dependent kinase inhibitor gene that encodes p27, in gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) appears to be associated with a worse prognosis.

Few Agents Better Than Somatostatin Analogs for Symptom Control in Carcinoid Syndrome

October 11th 2014

Somatostatin analogs remain the mainstay of medical therapy for symptom control in patients with carcinoid syndrome.

Subcutaneous Octreotide May Offer Better Option for Managing NETS Symptoms

October 11th 2014

A subcutaneous depot formulation of octreotide has a rapid onset, greater bioavailability, and a similar duration of effect compared with intramuscular octreotide long-acting repeatable.

Axitinib Shows Promise in Carcinoid Tumors

October 10th 2014

The rate of PFS with axitinib in patients with advanced carcinoid tumors is promising.

Everolimus Improves Outcomes in Pancreatic Neuroendocrine Tumors

October 10th 2014

Treatment with the mTOR inhibitor everolimus improved overall survival by 6.34 months over placebo for patients with pancreatic neuroendocrine tumors.

Dr. Reidy-Lagunes on Determining the Site of Unknown Primary in Metastatic NETs

October 10th 2014

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis looking at a practical method of determining the site of unknown primary in metastatic neuroendocrine tumors (NETs).

Dr. Pommier Discusses Challenges Associated With the Treatment of Carcinoid Syndrome

October 10th 2014

Rodney F. Pommier, MD, professor of surgery, director, Neuroendocrine Tumor Program, Oregon Health & Science University, discusses challenges associated with the treatment of carcinoid syndrome.

Combination Therapies, Novel Targeted Agents Are Focus of Pancreatic NET Studies

October 10th 2014

Selection of first-line treatments and the rational sequencing of therapies are among the unresolved questions in the treatment of pancreatic neuroendocrine tumors.

Dr. Yao on Takeaways From the RADIANT-3 Trial

October 10th 2014

James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses key takeaways from the RADIANT-3 trial for a community oncologist.

Dr. Kunz on Sequencing Agents for Pancreatic NETs

October 10th 2014

Pamela L. Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, discusses sequencing agents for the treatment of pancreatic NETs.